- 17 records/ articles analyzed.
- Below table covers articles (1 to 8), which are talking about inhibition or stimulation of HSL by the chemical compounds.
|S.No.||Database/ Accession Number||Focus||Compounds||HSL Activity/ Expression||Function of the compounds||Disease/Disorder (to be treated/ associated with)||Dolcera summary|
|1||BIOSIS / 2006:234207||Expression of the HSL gene by the PPAR gamma and PPAR gamma agonists (rosiglitazone and pioglitazone) in the cultured hepatic cells and differentiating preadipocytes.||Rosiglitazone||Up-regulation||Rosiglitazone up-regulates the HSL gene in liver and skeleton muscle (from an experimental obese rat model).||Type 2 diabetes||This study is focused on expression of the HSL gene by PPAR gamma and PPAR gamma agonists (rosiglitazone and pioglitazone) in the cultured hepatic cells and differentiating preadipocytes. Rosiglitazone up-regulates the HSL gene. In conclusion, the study suggests that HSL may be a newly identified PPAR gamma target gene, and up-regulation of HSL may be an important mechanism involved in action of PPAR gamma agonists in type 2 diabetes.|
|2||BIOSIS / 2004:316145||Inhibitors of hormone sensitive lipase.||(5-(2H)-isoxazolonyl) ureas||Inhibition||Inhibits HSL||Diabetes||(5-(2H)-isoxazolonyl) ureas, inhibitors of hormone-sensitive lipase, an enzyme of potential importance in the treatment of diabetes.|
|3||BIOSIS / 2004:256580||Inhibitors of hormone sensitive lipase||Carbazates||Inhibition||Inhibits HSL||Peripheral insulin resistance (in obese, prediabetic and diabetic individuals)||Carbazates, inhibitors of the catalytic activity of HSL. HSL is a potential pharmacological target for the prevention of peripheral insulin resistance in obese, prediabetic and diabetic individuals.|
|4||BIOSIS / 2004:136651||Inhibitors of hormone sensitive lipase||Methyl-phenyl- carbamoyl-triazoles||Inhibition||Inhibits HSL||Type 2 diabetes, metabolic syndrome, and impaired glucose tolerance||Methyl-phenyl-carbamoyl-triazoles are potent HSL inhibitors. HSL regulates fatty acid metabolism makes it an pharmacological target for the treatment of insulin resistant and dyslipidemic disorders where a decrease in delivery of fatty acids to the circulation is desirable in individuals with type 2 diabetes, metabolic syndrome, or impaired glucose tolerance.|
|5||BIOSIS / 2002:429399||Inhibitors of hormone sensitive lipase||Cyclipostins||Inhibition||Inhibits HSL||Type 2 diabetes||Cyclipostins are inhibitors of hormone-sensitive lipase (HSL). HSL is a key enzyme of lipid metabolism and its control is therefore a target in the treatment of diabetes mellitus.|
|6||EMBASE / 1998360072||Moderate dose of fish oil on glycemic control and in vivo insulin action in type 2 diabetic men||Fish oil||Up-regulation (increase the amount of mRNA HSL in adipose tissue)||Up-regulates HSL expression||Type 2 diabetes||This study is on effect of a moderate dose of fish oil on glycemic control and in vivo insulin action in type 2 diabetic men with elevated plasma triacylglycerols. In conclusion, A moderate dose of fish oil did not lead to deleterious effects on glycemic control or whole-body insulin sensitivity in type 2 diabetic men. Fish oil tended to increase the amount of mRNA HSL in adipose tissue.|
|7||DISSABS / 2006:21112||Inhibitors of hormonesensitive lipase||Cyclipostins||Inhibition||Inhibits HSL||Type 2 diabetes||Article is on synthesis of cyclipostins. Cyclipostins are novel class of natural product possesses strong inhibitory action against hormone-sensitive lipase and has potential in the development of therapeutic agents to regulate lipolysis for the treatment of noninsulin-dependent diabetes mellitus (NIDDM).|
|8||DISSABS / 1999:39502||Beta3-adrenergic agonist||Trecadrine||Stimulation||Stimulates HSL activity||Diabetes, and obesity||Beta3-adrenergic agonist, trecadrine increases the activity of hormone sensitive lipase and the consumption of oxygen in vitro in white fat.|